Gilead announced today that the PURPOSE 2 study of twice yearly lenacapavir injections as pre-exposure prophylaxis (PrEP) reduced HIV infections by 96% compared to daily oral PrEP. Fenway Health was a PURPOSE 2 study trial site. BOSTON, Sept. 12, 2024 /PRNewswire-PRWeb/ — Gilead…
Gilead announced today that the PURPOSE 2 study of twice yearly lenacapavir injections as pre-exposure prophylaxis (PrEP) reduced HIV infections by 96% compared to daily oral PrEP. Fenway Health was a PURPOSE 2 study trial site. BOSTON, Sept. 12, 2024 /PRNewswire-PRWeb/ — Gilead…